CPC C07K 16/2803 (2013.01) [A61P 35/00 (2018.01); A61K 38/00 (2013.01); C07K 2317/24 (2013.01); C07K 2317/77 (2013.01); C07K 2317/92 (2013.01)] | 14 Claims |
1. An anti-Siglec-7 antibody that binds to Siglec-7 and comprises:
(a) an HCDR1 sequence GYDFSNF (SEQ ID NO:79), an HCDR2 sequence YPGDGE (SEQ ID NO:80), an HCDR3 sequence DDYLRAMDY (SEQ ID NO:81), an an LCDR1 sequence RASGNIHNYLA (SEQ ID NO:93), an LCDR2 sequence SAKRLES (SEQ ID NO:94), and an LCDR3 sequence QHFWSSPYT (SEQ ID NO:95);
(b) an HCDR1 sequence GYDFSNF (SEQ ID NO:79), an HCDR2 sequence YPGDGE (SEQ ID NO:80), an HCDR3 sequence DDYLRAMDY (SEQ ID NO:81), an LCDR1 sequence RASQNIHNYLA (SEQ ID NO:100), an LCDR2 sequence SAKRLES (SEQ ID NO:94), and an LCDR3 sequence QHFWSSPYT (SEQ ID NO:95);
(c) an HCDR1 sequence GYDFSNF (SEQ ID NO:79), an HCDR2 sequence YPGDGE (SEQ ID NO:80), an HCDR3 sequence DDYLRAMDV (SEQ ID NO:91), an LCDR1 sequence RASQNIHNYLA (SEQ ID NO:100), an LCDR2 sequence SAKRLES (SEQ ID NO:94), and an LCDR3 sequence QHFWSSPYT (SEQ ID NO:95);
(d) an HCDR1 sequence GYDFSNF (SEQ ID NO:79), an HCDR2 sequence YPGDGE (SEQ ID NO:80), an HCDR3 sequence DDYLRAMDV (SEQ ID NO:91), an LCDR1 sequence RASQNIHNYLA (SEQ ID NO:100), an LCDR2 sequence SAKRLED (SEQ ID NO:103), and an LCDR3 sequence QHFWSSPYT (SEQ ID NO:95);
(e) an HCDR1 sequence GYDFSNF (SEQ ID NO:79), an HCDR2 sequence YPGDGE (SEQ ID NO:80), an HCDR3 sequence DDYLRAMDI (SEQ ID NO:92), an LCDR1 sequence RASGNIHNYLA (SEQ ID NO:93), an LCDR2 sequence SAKRLES (SEQ ID NO:94), and an LCDR3 sequence QHFWSSPYT (SEQ ID NO:95);
(f) an HCDR1 sequence GYDFSNF (SEQ ID NO:79), an HCDR2 sequence YPGDGE (SEQ ID NO:80), an HCDR3 sequence DDYLRAMDI (SEQ ID NO:92), an LCDR1 sequence RASGNIHNYLA (SEQ ID NO:93), an LCDR2 sequence SAKRLED (SEQ ID NO:103), and an LCDR3 sequence QHFWSSPYT (SEQ ID NO:95);
(g) an HCDR1 sequence GYDFSNF (SEQ ID NO:79), an HCDR2 sequence YPGDGE (SEQ ID NO:80), an HCDR3 sequence DDYLRAMDI (SEQ ID NO:92), an LCDR1 sequence RASQNIHNYLA (SEQ ID NO:100), an LCDR2 sequence SAKRLES (SEQ ID NO:94), and an LCDR3 sequence QHFWSSPYT (SEQ ID NO:95);
(h) an HCDR1 sequence GYDFSNF (SEQ ID NO:79), an HCDR2 sequence YPGDGE (SEQ ID NO:80), an HCDR3 sequence DDYLRAMDI (SEQ ID NO:9 2), an LCDR1 sequence RASQNIHNYLA (SEQ ID NO:100), an LCDR2 sequence SAKRLED (SEQ ID NO:103), and an LCDR3 sequence QHFWSSPYT (SEQ ID NO:95);
(i) an HCDR1 sequence GYDFSNY (SEQ ID NO:89), an HCDR2 sequence YPGDGE (SEQ ID NO:80), an HCDR3 sequence DDYLRAMDI (SEQ ID NO:92), an LCDR1 sequence RASGNIHNYLA (SEQ ID NO:93), an LCDR2 sequence SAKRLES (SEQ ID NO:94), and an LCDR3 sequence QHFWSSPYT (SEQ ID NO:95);
(j) an HCDR1 sequence GYDFSNY (SEQ ID NO:89), an HCDR2 sequence YPGDGE (SEQ ID NO:80), an HCDR3 sequence DDYLRAMDI (SEQ ID NO:92), an LCDR1 sequence RASQNIHNYLA (SEQ ID NO:100), an LCDR2 sequence SAKRLES (SEQ ID NO:94), and an LCDR3 sequence QHFWSSPYT (SEQ ID NO:95);
(k) an HCDR1 sequence GYDFSNY (SEQ ID NO:89), an HCDR2 sequence YPGDGE (SEQ ID NO:80), an HCDR3 sequence DDYLRAMDY(SEQ ID NO:81), an LCDR1 sequence RASQNIHNYLA (SEQ ID NO:100), an LCDR2 sequence SAKRLES (SEQ ID NO:94), and an LCDR3 sequence QHFWSSPYT (SEQ ID NO:95); or
(l) an HCDR1 sequence GYDFSNF (SEQ ID NO:79), an HCDR2 sequence YPGDGE (SEQ ID NO:80), an HCDR3 sequence DDYLRAMDV (SEQ ID NO:91), an LCDR1 sequence RASGNIHNYLA (SEQ ID NO:93), an LCDR2 sequence SAKRLES (SEQ ID NO:94), and an LCDR3 sequence QHFWSSPYT (SEQ ID NO:95).
|